ANGI-01 ALTERATION IN IMMUNE REGULATORY CELLS BEFORE AND AFTER TREATMENT BY STUPP REGIMEN WITH OR WITHOUT BEVACIZUMAB FOR GLIOBLASTOMA

BACKGROUND: In our previous study, bevacizumab (Bev), a humanized anti- vascular endothelial growth factor monoclonal antibody, downregulated the expression of programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) immune checkpoint molecules, suppressed the infiltration of immunosupp...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neurooncol Adv
Päätekijät: Tanaka, Toshihide, Tamura, Ryota, Yamamoto, Yohei, Morimoto, Yukina, Teshigawara, Akihiko, Tochigi, Satoru, Hasegawa, Yuzuru, Takei, Jun, Akasaki, Yasuharu, Sasaki, Hikaru, Murayama, Yuichi
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2019
Aiheet:
Abstracts
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7213323/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdz039.019
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia